Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety, efficacy, and long-term follow-up evaluation of perioperative epirubicin, Cisplatin, and capecitabine chemotherapy in esophageal resection for adenocarcinoma.
van der Sluis PC, Ubink I, van der Horst S, Boonstra JJ, Voest EE, Ruurda JP, Borel Rinkes IH, Wiezer MJ, Schipper ME, Siersema PD, Los M, Lolkema MP, van Hillegersberg R. van der Sluis PC, et al. Among authors: ubink i. Ann Surg Oncol. 2015 May;22(5):1555-63. doi: 10.1245/s10434-014-4120-9. Epub 2015 Jan 7. Ann Surg Oncol. 2015. PMID: 25564156
Adding preoperative radiotherapy plus cetuximab to perioperative chemotherapy for resectable esophageal adenocarcinoma: a single-center prospective phase II trial.
Ubink I, van der Sluis P, Schipper M, Reerink O, Voest E, Borel-Rinkes I, Wijrdeman H, Vleggaar F, Agterof M, Overkleeft E, Siersema P, van Hillegersberg R, Lolkema MP. Ubink I, et al. Oncologist. 2014 Jan;19(1):32-3. doi: 10.1634/theoncologist.2013-0254. Epub 2013 Dec 12. Oncologist. 2014. PMID: 24335595 Free PMC article. Clinical Trial.
The time to progression ratio: a new individualized volumetric parameter for the early detection of clinical benefit of targeted therapies.
Cirkel GA, Weeber F, Bins S, Gadellaa-van Hooijdonk CG, van Werkhoven E, Willems SM, van Stralen M, Veldhuis WB, Ubink I, Steeghs N, de Jonge MJ, Langenberg MH, Schellens JH, Sleijfer S, Lolkema MP, Voest EE. Cirkel GA, et al. Among authors: ubink i. Ann Oncol. 2016 Aug;27(8):1638-43. doi: 10.1093/annonc/mdw223. Epub 2016 May 27. Ann Oncol. 2016. PMID: 27234642 Free article. Clinical Trial.
Imatinib treatment of poor prognosis mesenchymal-type primary colon cancer: a proof-of-concept study in the preoperative window period (ImPACCT).
Ubink I, Bloemendal HJ, Elias SG, Brink MA, Schwartz MP, Holierhoek YCW, Verheijen PM, Boerman AW, Mathijssen RHJ, de Leng WWJ, de Weger RA, van Grevenstein WMU, Koopman M, Lolkema MP, Kranenburg O, Borel Rinkes IHM. Ubink I, et al. BMC Cancer. 2017 Apr 19;17(1):282. doi: 10.1186/s12885-017-3264-y. BMC Cancer. 2017. PMID: 28424071 Free PMC article.
In Patients Undergoing CRS/HIPEC for Colorectal Adenocarcinoma with Peritoneal Metastases, Presence of Ascites on Computed Tomography Imaging is not a Prognostic Marker for Survival.
Said I, Ubink I, Ewalds RSG, Arkesteijn JGT, Verheul HMW, de Wilt JHW, Dekker HM, Bremers AJA, de Reuver PR. Said I, et al. Among authors: ubink i. Ann Surg Oncol. 2022 Aug;29(8):5256-5262. doi: 10.1245/s10434-022-11718-7. Epub 2022 Apr 16. Ann Surg Oncol. 2022. PMID: 35430666 Free PMC article.
Associations of non-pedunculated T1 colorectal adenocarcinoma outcome with consensus molecular subtypes, immunoscore, and microsatellite status: a multicenter case-cohort study.
Haasnoot KJC, Backes Y, Moons LMG, Kranenburg O, Trinh A, Vermeulen L, Noë M, Tuynman JB, van Lent AUG, van Ginneken R, Seldenrijk CA, Raicu MG, Trumpi K, Ubink I, Milne AN, Boonstra JJ, Groen JN, Schwartz MP, Wolfhagen FHJ, Geesing JMJ, Ter Borg F, Brosens LAA, van Bergeijk J, Spanier BWM, de Vos Tot Nederveen Cappel WH, Kessels K, Seerden TCJ, Vleggaar FP, Offerhaus GJA, Siersema PD, Elias SG, Laclé MM; Dutch T1 CRC Working Group. Haasnoot KJC, et al. Among authors: ubink i. Mod Pathol. 2020 Dec;33(12):2626-2636. doi: 10.1038/s41379-020-0598-9. Epub 2020 Jun 24. Mod Pathol. 2020. PMID: 32581367 Free article.
Detailed imaging and genetic analysis reveal a secondary BRAF(L505H) resistance mutation and extensive intrapatient heterogeneity in metastatic BRAF mutant melanoma patients treated with vemurafenib.
Hoogstraat M, Gadellaa-van Hooijdonk CG, Ubink I, Besselink NJ, Pieterse M, Veldhuis W, van Stralen M, Meijer EF, Willems SM, Hadders MA, Kuilman T, Krijgsman O, Peeper DS, Koudijs MJ, Cuppen E, Voest EE, Lolkema MP. Hoogstraat M, et al. Among authors: ubink i. Pigment Cell Melanoma Res. 2015 May;28(3):318-23. doi: 10.1111/pcmr.12347. Epub 2015 Jan 7. Pigment Cell Melanoma Res. 2015. PMID: 25515853
Consensus molecular subtype 4 (CMS4)-targeted therapy in primary colon cancer: A proof-of-concept study.
Peters NA, Constantinides A, Ubink I, van Kuik J, Bloemendal HJ, van Dodewaard JM, Brink MA, Schwartz TP, Lolkema MPJK, Lacle MM, Moons LM, Geesing J, van Grevenstein WMU, Roodhart JML, Koopman M, Elias SG, Borel Rinkes IHM, Kranenburg O. Peters NA, et al. Among authors: ubink i. Front Oncol. 2022 Sep 6;12:969855. doi: 10.3389/fonc.2022.969855. eCollection 2022. Front Oncol. 2022. PMID: 36147916 Free PMC article.
23 results